Form 4: Teva Pharmaceutical Industries CEO Richard Francis Executes Stock Sales to Cover Tax Obligations

CEO Richard Francis sold Teva Pharmaceutical Industries shares to cover tax withholding obligations related to vesting restricted share units, while also acquiring shares through the vesting of these units.

Summary

• On March 4th and 5th, 2025, Richard D. Francis, the President and CEO of Teva Pharmaceutical Industries, engaged in transactions involving the company's ordinary shares.
• These transactions included the acquisition of 50,223 shares through the vesting of restricted share units on March 4, 2025.
• Simultaneously, Francis sold shares to cover tax withholding obligations related to the vesting of these restricted share units.
• On March 4, 2025, 15,514 shares were sold at a weighted average price of $15.7346, and on March 5, 2025, 8,259 shares were sold at a weighted average price of $15.9132.
• Following these transactions, Francis directly owns 271,783 ordinary shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are routine and related to compensation and tax obligations. The sales are conducted under a pre-arranged plan, suggesting no immediate concern about the company's prospects.

Future Outlook

The reporting person will continue to vest in 50,223 restricted share units on March 4 of 2026, 2027 and 2028.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often tied to compensation packages and tax planning strategies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates